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Extraintestinal manifestations (EIM) involving joints, skin, eyes and liver represent an impor-
tant problem in the treatment of IBD patients. The aim of this study was to identify factors
that are associated with the occurrence of joint EIM and therefore allow an early diagnosis
and guide medical treatment.
Methods
We studied clinical and epidemiological data from 3298 patients included in the Swiss IBD
Cohort Study (SIBDCS), 1860 suffered from Crohn’s disease (CD) and 1438 from ulcerative
colitis or IBD unclassified (UC/IBDU).
Results
We found female gender as well as a longer disease duration and activity (specified as
CDAI or MTWAI, respectively) to be related to the appearance of arthritis/arthralgia, but also
sacroiliitis/ankylosing spondylitis in IBD patients. IBD patients with arthritis/arthralgia or
sacroiliitis/ankylosing spondylitis were more often treated with anti-TNF and patients with
arthritis/arthralgia underwent more often IBD-related surgeries. We revealed that eye or
skin EIM were more frequent in patients with arthritis/arthralgia or sacroiliitis/ankylosing
spondylitis. In multivariate analysis, we confirmed female gender, longer disease duration,
IBD-related surgery, presence of other EIM and treatment with anti-TNF to be independent
risk factors for the onset of arthritis/arthralgia in CD and UC/IBDU patients.
Conclusion
In this study, we demonstrated that markers for a more severe disease course were associ-
ated with the onset of joint EIM in IBD patients. Our data suggest that in particular females
under anti-TNF treatment and patients suffering from non-joint and/or IBD-related surgery
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should be close and carefully monitored for presence of arthritis or sacroiliitis/ankylosing
spondylitis.
Introduction
Up to 47% of all inflammatory bowel disease (IBD) patients suffer from extraintestinal mani-
festations (EIM) [1–3]. Musculoskelettal manifestations in general are the most common EIM
in IBD patients with peripheral arthritis being the most frequent subtype [2, 3]. It is obvious
that patients with a high-risk profile for such EIM should be closely monitored (as well as
treated early). Other organs affected by the intestinal disease are skin, bile duct and eyes [3].
EIM may occur before the actual intestinal disease is diagnosed [1–3]. Furthermore, presence
of EIM plays an important role in a patient’s quality of life [4–6].
IBD-associated musculoskelettal EIMs belong to the group of spondyloarthritis (SpA).
Depending on their main symptoms, SpA can be divided into axial and peripheral SpA which
both can occur in IBD patients either independently or in combination [7]. Peripheral SpA
encompasses a number of different musculoskeletal entities: arthralgia, peripheral arthritis,
enthesitis and dactylitis. In general, IBD-associated peripheral arthritis is a non-erosive,
inflammatory arthropathy and can in many cases be grouped into two subtypes according to
Orchard et al. [8] Patients suffering from type 1 exhibit joint pain as well as swelling or effusion
that affects less than five joints, most frequently the large joints of the lower limb. Symptoms
are often acute, self-limiting, without permanent joint damage and correlate with acute IBD
flares. Patients suffering from type 2 exhibit joint pain that affects more than five joints with a
symmetric distribution that is predominantly affecting the upper limbs. Symptoms are inde-
pendent of luminal IBD inflammation and often continue for months or years. Prognosis of
peripheral arthritis is mainly a good one and chronic or erosive complications are rare [9, 10].
The main feature of IBD-related axial spondyloarthritis (axSpA) is the involvement of the axial
skeleton (sacroiliitis and spondylitis). AxSpA can be divided in a non-radiographic and a
radiographic form, depending on whether conclusive evidence for sacroiliacal joint damage
can be seen on conventional radiographs. The radiographic form corresponds to ankylosing
spondylitis (AS). Prognosis of axial disease is highly variable and linked not only to inflamma-
tion, but also to new bone formation, potentially leading to ankyloses. The treatment of axial
and peripheral SpA in IBD patients includes non-pharmacological and pharmacological treat-
ments. While non-steroidal anti-inflammatory drugs can be used for all manifestations, con-
ventional disease modifying anti-rheumatic drugs (sulfasalazine, methotrexate, leflunomide)
are only effective in the presence of peripheral arthritis (objective synovitis) and not effective
in other peripheral joint manifestations like arthralgia, enthesitis and dactylitis or in axial dis-
ease. Depending on disease activity, TNF inhibitors may be indicated in refractory cases [11].
Of note, in IBD, only 10% of all patients with joint complaints finally fullfil the SpA criteria
[12].
Crohn’s disease (CD), female gender and higher age of the patients were found to be predis-
posing factors for developing joint EIM in IBD patients [13] and recent studies also suggest a
genetic background for developing joint EIM [14]. The so-called gut-joint axis hypothesizes
that activated lymphocytes from the gut migrate to the joints and initiate the onset of EIM in
the joints [5, 15, 16]. To optimize patient care, it is important to identify predisposing factors
for the occurrence of EIM in IBD patients in order to initiate an appropriate and early treat-
ment of both the actual disease and the EIM. This might help to prevent a more severe disease
IBD and joint manifestations
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course. For this purpose, we analyzed the patient data of the well-characterized patient collec-
tive of the SIBDCS to identify correlation between the presence of joint EIM and epidemiolog-
ical and clinical risk factors.
Patients and methods
Patient data
Data were collected from the Swiss nationwide Swiss IBD Cohort Study (SIBDCS) patient
database. The SIBDCS represents a multicenter, prospective observational, population-based
study that is funded by the Swiss National Science Foundation (SNSF). The SIBDCS was
implemented in all regions of Switzerland in 2006 by a multidisciplinary effort by gastroenter-
ologists, pathologists, psychologists and bioinformatics specialists. For inclusion in the
SIBDCS, IBD patients must demonstrate an IBD diagnosis established at least 4 months prior
to study entry. Patient data are prospectively collected via specific questionnaires once a year
and submitted to a central database. Questionnaires are exhibited in the Supplemental material
section of the manuscript. Inclusion and exclusion criteria have been described in detail previ-
ously [17]. In our study, we included 3298 IBD-patients in total. 1860 were CD and 1438 were
UC/IBD unidentified (IBDU) patients. Data on musculoskeletal conditions thought to be
related to IBD were collected through a questionnaire completed at enrollment and follow-up
visits by either a gastroenterologist, a study nurse or a research assistant. The presence of
arthralgia/peripheral arthritis could be indicated either as yes or still ongoing, as was the pres-
ence of sacroiliitis/ankylosing spondylitis. No specific training for evaluation of musculoskele-
tal conditions was provided to the assessors. We have therefore chosen to only look at
peripheral joint manifestations.
Study design
First, the total patient collective of 3298 patients was divided into two groups: patients with
arthritis/arthralgia vs. patients without any signs arthritis/arthralgia. In a second step, we ana-
lyzed the total patient collective of 3298 patients according to the presence or absence of
sacroiliitis/ankylosing spondylitis.
We then analyzed the association of arthritis/arthralgia or sacroiliitis/ankylosing spondyli-
tis, respectively and the following factors: 1) Epidemiological factors such as gender, age at
diagnosis, age at latest follow-up, disease duration, family history, smoking status (at diagnosis
and latest follow-up) and BMI. 2) Disease characteristics such as initial disease location, last
disease location, disease activity (Modified Truelove and Witts activity index, [MTWAI] and
CD (Crohn’s disease activity index, [CDAI]) and complications as stenosis, fistula, abscess,
anemia and Vitamin B12 levels (at latest follow-up) as well as other EIM and IBD-related sur-
gery. 3) Medical treatment including the following medications: 5-ASA, antibiotics, steroids,
immunomodulators (azathioprine, 6-mercaptopurin), anti-TNF, methotrexate, calcineurin
inhibitors. 4) Longitudinal data on joint EIM. Non-joint EIM included erythema nodosum,
pyoderma gangrenosum, oral and aphtous ulcers, uveitis, iritis and PSC. Malabsorption syn-
drome with consequent anemia and vitamin B12 deficiency was also considered as a complica-
tion. To assess disease activity for UC (Modified Truelove and Witts activity index, MTWAI)
and CD (Crohn’s disease activity index, CDAI), disease activity measures were normalized to a
value between 0 and 100 and expressed as an activity index. IBD medication was documented
by the treating physician in the specific SIBDC questionnaires at patient inclusion and follow-
up visits as well as by the patient questionnaires.
IBD and joint manifestations
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Statistical analysis
All statistical analyses were carried out using the Stata Software (v. 14.2, StataCorp, College
Station, TX, USA) and the R software (v. 3.3.1, The R Foundation for Statistical Computing,
Vienna, Austria). Normal QQ-plots were used to assess distribution of continuous data.
Gaussian-distributed data were reported as mean, standard deviation and range, while non-
Gaussian data were presented as median, interquartile range and range. Differences in means
between two independent groups for Gaussian-distributed data were assessed using the Stu-
dent’s t-test. Differences in distribution locations between two independent groups for non-
Gaussian data were assessed using the Mann-Whitney-Wilcoxon rank-sum test. Categorical
data were presented as raw frequencies and relative percentages. Differences in distributions
for categorical data between two or more groups were assessed using the Chi-square test, or
the Fisher’s exact test in case of insufficient sample size.
Time-to-event data were analysed using the Kaplan-Meier estimator to deal with interval-
censored data. Results were presented as cumulative proportion curves.
Multivariate logistic regression was used to assess the association of multiple factors with
the occurrence of joint EIM. First, all factors with univariate p-value < 0.200 were included
into the multivariate model. Non-significant factors (p>0.05) were then excluded from the
model one-by-one, until all remaining factors were significant. In a last step, all factors that
were left aside were once more inserted one-by-one into the model and kept if proven signifi-
cant, while checking for model consistency at each step of the procedure.
Ethical considerations
The IBD cohort study has been approved by the respective ethics committees in Switzerland
(Ethics Committee of the Canton Zu¨rich: EK-1316). All patients signed an informed consent,
confirmed their participation in the cohort study at the time of enrollment and gave informed
consent for data collection and analysis for research purposes. For inclusion of minors,
obtained consent had been provided from parents or guardians. The current sub-study has
been evaluated and approved by the scientific board of SIBDCS.
Results
Epidemiology of arthritis/arthralgia in CD patients
From the 1860 CD patients included in the SIBDC, 907 respectively 48.8% suffered from
arthritis/arthralgia during their disease course. Female CD patients were found to be signifi-
cantly more often affected with joint EIM than men. Age at diagnosis of CD patients with joint
manifestations was significantly higher than the age at diagnosis of CD patients without joint
EIM (median 27 vs. 25 years). Furthermore, patients with arthritis/arthralgia included in the
SIBDCS suffered from a significantly longer disease duration of 15 years than patients without
arthritis/arthralgia with only 11 years (Table 1). BMI and smoking status showed no associa-
tion with the presence of arthritis/arthralgia.
Disease characteristics in CD patients
We did not find any association of arthritis/arthralgia and initial disease location. However,
ileocolic inflammation (L3) was the most common disease location for both patient groups at
the beginning of the disease. CDAI (Crohn’s disease activity index) at enrollment (median 51
vs. 21) as well as at follow-up (33 vs. 13) was significantly higher in patients with arthritis/
arthralgia (Table 2).
IBD and joint manifestations
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Disease complications and other EIM in CD patients
CD-related complications such as perianal fistula, other fistula, any fistula and abscesses
revealed not to be associated to joint EIM in CD patients. However, CD patients with arthritis/
arthralgia suffered significantly more often from a structuring disease course and a subsequent
stenosis. Subsequently, patients suffering from arthritis/arthralgia underwent intestinal resec-
tion more often than patients without arthritis/arthralgia. Yet, there was no difference detected
between the two groups for specific fistula/abscess surgery. This implies that patients with
arthritis/arthralgia might preferably present with a B2 rather than a B3 disease behavior.
To assess an association of malabsorption with the onset of arthritis/arthralgia in CD
patients, we next analyzed, whether anemia and low vitamin B12 serum levels were more fre-
quent in patients with or without arthritis/arthralgia. During SIBDCS follow-up, anemia was
more often observed in patients with arthritis/arthralgia as compared to patients without. Vita-
min B12 levels at latest follow-up did not indicate a deficit in both patient groups (with and
without joint EIM). However patients with arthritis/arthralgia had higher levels of serum vita-
min B12 (250 vs. 231 pmol/l) overall. Furthermore, patients with arthritis/arthralgia received
more often a vitamin B12 supplementation at any time during the observation period than
patients with no arthritis/arthralgia, likely because of the more severe disease and therefore
higher risk for malabsorption.
We found other EIM to be significantly associated with the existence of arthritis/arthralgia
in CD patients. Uveitis/Iritis (18.3% vs. 4.3%), erythema nodosum (11.9% vs. 3.7%) and aph-
tous/oral ulcers (20.6% vs. 5.8%) were significantly more frequent in CD patients with existing
arthritis/arthralgia. In contrast, pyoderma gangrenosum and PSC did not show a significant
difference between both of the groups (Table 2).
Treatment history in CD patients
We further analyzed the treatment history of CD patients with and without joint EIM. Patients
with arthritis/arthralgia received significantly more often 5-ASA, antibiotics, steroids, immu-
nomodulators and anti-TNF (Table 3). To further validate our findings, we next performed a
Table 1. Relation between epidemiological factors (gender, age, disease duration) and joint manifestations in CD
patients.
No Joint EIM Joint EIM All CD patients pvalue
Number of patients 953 (51.2) 907 (48.8) 1860 (100.0)
Gender
Male 520 (54.6) 366 (40.4) 886 (47.6)
Female 433 (45.4) 541 (59.6) 974 (52.4) <0.001
Age at diagnosis [y] (median,IQR, range) 25, 20–35, 4–81 27, 20–38, 1–81 26, 20–37, 1–81 0.004
Age at latest follow-up [y] (median, IQR, range) 40, 31–53, 17–89 48, 36–60, 16–94 44, 33–57, 16–94 <0.001
Disease duration [y]
(median, IQR, range)
11, 6–20, 0–53 15, 9–24, 0–57 13, 7–22, 0–57 <0.001
Smoking status at diagnosis
Non-smoker 488 (51.2) 426 (47.0) 914 (49.1)
Smoker 420 (44.1) 445 (49.1) 865 (46.5)
Unknown 45 (4.7) 36 (4.0) 81 (4.4) 0.091
Smoking status at latest follow up
Non-Smoker 662 (69.5) 601 (66.3) 1263 (67.9)
Smoker 282 (29.6) 302 (33.3) 584 (31.4)
Unknown 9 (0.9) 4 (0.4) 13 (0.7) 0.110
https://doi.org/10.1371/journal.pone.0211554.t001
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multivariate logistic regression analysis for possible factors being associated with the presence
of arthritis/arthralgia in CD patients. Here, we detected that female gender, older age at diag-
nosis, a longer disease duration, IBD-related surgery not due to fistula or abscesses, 5-ASA
treatment, treatment with steroids, treatment with anti-TNF as well as the presence of other
EIM were independently associated with the occurrence of arthritis/arthralgia in the CD
patients of the SIBDCS patient collective (Table 4).
Table 2. Disease characteristics (location and disease activity), disease complications (fistula, abscess, stenosis), CD-related surgery and other EIMs in relation to
joint EIM in CD patients.
No Joint EIM Joint EIM All CD patients pvalue
Number of patients 953 (51.2) 907 (48.8) 1860 (100.0)
Initial disease location
L1 244 (25.6) 201 (22.2) 445 (23.9)
L2 184 (19.3) 182 (20.1) 366 (19.7)
L3 414 (43.4) 415 (45.8) 829 (44.6)
L4 only 7 (0.7) 7 (0.8) 14 (0.8)
Unclear/Unknown 104 (10.9) 102 (11.3) 206 (11.1) 0.549
Last disease location
L1 284 (29.8) 237 (26.1) 521 (28.0)
L2 266 (27.9) 290 (32.0) 556 (29.9)
L3 267 (28.0) 246 (27.1) 513 (27.6)
L4 only 13 (1.4) 34 (3.4) 47 (2.5)
Unclear/Unknown 123 (12.9) 100 (11.0) 223 (12.0) 0.002
CDAI at enrolment (median, IQR, range) 21, 6–53,0–280 51, 26–93, 0–450 34, 12–76, 0–450 <0.001
CDAI at latest follow-up (median, IQR, range) 13, 6–26, 0–218 33, 11–65, 0–395 21, 6–51, 0–395 <0.001
CD-related complications
Perianal Fistula 235 (24.7) 246 (27.1) 481 (25.9) 0.225
Other Fistula 145 (12.2) 158 (17.4) 303 (16.3) 0.198
Any Fistula 327 (34.3) 323 (35.6) 650 (34.9) 0.557
Abscess 223 (23.4) 238 (26.2) 461 (24.8) 0.156
Stenosis 3876 (40.5) 418 (46.1) 804 (43.2) 0.015
CD-related surgery
Intestinal resection 366 (38.4) 405 (44.7) 771 (41.5) 0.006
Fistula/Abscess surgery 233 (24.5) 235 (25.9) 468 (25.2) 0.468
Any Surgery 469 (49.2) 486 (53.6) 955 (51.3) 0.059
Anemia
During SIBDCS follow-up 242 (26.0) 315 (35.1) 557 (30.5) <0.001
At latest follow-up 85 (11.3) 98 (13.7) 183 (12.5) 0.170
Vit. B12 level at latest follow-up [pmo]/l)
(median, IQR, range)
231, 171–309, 37–2435 250, 186–342, 28–1500 242, 178–325, 28–2435 0.003
Ever received Vit. B12 Suppl. 334 (45.6) 459 (57.0) 793 (51.6) <0.001
Extraintestinal manifestations
Uveitis/Iritis 41 (4.3) 166 (18.3) 207 (11.1) <0.001
Pyoderma Gangrenosum 10 (1.0) 19 (2.1) 29 (1.6) 0.069
Erythema Nodosum 35 (3.7) 108 (11.9) 143 (7.7) <0.001
Aphtous/oral ulcers 55 (5.8) 187 (20.6) 242 (13.0) <0.001
Ankylosing spondilitis 18 (1.9) 110 (12.1) 128 (6.9) <0.001
PSC 7 (0.7) 5 (0.6) 12 (0.6) 0.775
any of the above 143 (15.09 414 (45.6) 557 (29.9) <0.001
https://doi.org/10.1371/journal.pone.0211554.t002
IBD and joint manifestations
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Epidemiology of joint manifestations in UC/IBDU patients
Out of 1438 UC/IBDU patients, 34.6% (498 patients; 231 male and 267 female patients, respec-
tively) suffered from arthritis/arthralgia. Similar to CD patients, age at diagnosis of UC/IBDU
patients with arthritis/arthralgia was slightly higher as compared to UC/IBDU patients without
arthritis/arthralgia (31 vs. 30 years). Median disease duration for patients with arthritis/
arthralgia was 13 years, while it was only 11 years in patients without arthritis/arthralgia. In
contrast to our findings for CD patients, smoking at diagnosis of UC/IBDU patients was sig-
nificantly related to the presence of arthritis/arthralgia (Table 5).
Disease characteristics in UC/IBDU patients
We detected no difference between initial and last disease location and appearance of arthritis/
arthralgia in UC/IBDU patients. However, disease activity at enrollment and at latest follow-
Table 3. Relation between treatment history and joint manifestations in CD patients.
No Joint EIM Joint EIM All CD patients pvalue
Number of patients 953 (51.2) 907 (48.8) 1860 (100.0)
Treatment history
5-ASA 489 (51.3) 580 (63.9) 1069 (57.5) <0.001
Antibiotics 143 (15.0) 197 (21.7) 340 (18.3) <0.001
Steroids 781 (82.0) 821 (90.5) 1602 (86.1) <0.001
Immunomodulators 750 (78.7) 764 (84.2) 1514 (81.4) 0.002
Anti-TNF 543 (57.0) 637 (70.2) 1180 (63.4) <0.001
Calcineurin inhibitors 13 (1.4) 23 (2.5) 36 (1.9) 0.067
https://doi.org/10.1371/journal.pone.0211554.t003
Table 4. Multivariate logistic regression results for CD patients.
Outcome: Joint EIM OR (95% CI) pvalue
Gender
Male 1 (ref)
Female 1.711 (1.314–2.229) <0.001
Age at diagnosis [per year] 1.030 (1.020–1.040) <0.001
Disease duration [per year] 1.048 (1.032–1.063) <0.001




Non (ref) 1 (ref)
Yes 0.743 (0.556–0.993) 0.045
5-ASA treatment
Never (ref) 1 (ref)
Yes 1.340 (1.017–1.766) 0.038
Steroids treatment
Never (ref) 1 (ref)
Yes 1.837 (1.163–2.900) 0.009
Anti-TNF treatment
Never (ref) 1 (ref)
Yes 1.693 (1.265–2.265) <0.001
Other EIM
No (ref) 1 (ref)
Yes 4.710 (3.494–6.349) <0.001
https://doi.org/10.1371/journal.pone.0211554.t004
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up was significantly higher for UC/IBDU patients with arthritis/arthralgia compared to
patients without arthritis/arthralgia. Median MTWAI at enrollment for patients with arthritis/
arthralgia was 3 and the median for patients without arthritis/arthralgia was 2 (Median
MTWAI at latest follow-up: 2 vs. 1; Table 6).
Disease complications and other EIM in UC/IBDU patients
Significantly more patients with arthritis/arthralgia ever had an UC/IBDU-related surgery,
likely colectomy, compared to patients without arthritis/arthralgia. Additionally, patients with
arthritis/arthralgia received more often vitamin B12 supplementation than patients without
arthritis/arthralgia, although there was no difference in vitamin B12 levels at latest follow-up
or in the presence of anaemia between the two groups. In accordance with previous data and
our findings in CD patients, UC/IBDU patients with arthritis/arthralgia more frequently suf-
fered from other EIM. 10.4% vs. 3.0% presented with uveitis/iritis, 3.0% vs. 1.1% with pyo-
derma gangrenosum, 7.4% vs. 1.5% with erythema nodosum, 11.4% vs. 2.3% with aphtous/
oral ulcers and 6.0% vs. 1.5% with ankylosing spondylitis. No difference between the groups
was detected for the presence of PSC (Table 6).
Treatment history and joint manifestations in UC/IBDU patients
Antibiotics, steroids, immunomodulators, anti-TNF and calcineurin inhibitors were signifi-
cantly more often used in patients with arthritis/arthralgia. The use of 5-ASA was similar
between the groups (Table 7). To further validate our findings, we next performed a multivari-
ate logistic regression analysis for possible factors being associated with the presence of arthri-
tis/arthralgia in UC/IBDU patients. Here, similar to CD patients, we identified female gender,
older age at diagnosis, longer disease duration, IBD-related surgery, treatment with anti-TNF
as well as the presence of other EIM to be independently associated with the presence of arthri-
tis/arthralgia in the UC/IBDU. Additionally, also smoking was associated with an increased
risk for arthritis/arthralgia in UC/IBDU patients (Table 8).
Table 5. Relation between epidemiological factors and the presence of joint EIM in UC/IBDU patients.
No Joint EIM Joint EIM All UC/IBDU pat. pvalue
Number of patients 940 (65.4) 498 (34.6) 1438 (100.0)
Gender
Male 542 (27.7) 231 (46.4) 773 (53.8)
Female 398 (42.3) 267 (53.6) 665 (46.2) <0.001
Age at diagnosis [y] (median,IQR, range) 30, 23–40, 3–83 31, 25–42, 10–
80
31, 23–41, 3–83 0.032






46, 36–57, 17–89 <0.001
Disease duration [y]
(median, IQR, range)
11, 6–17, 0–59 13, 9–21, 0–52 12, 7–19, 0–59 <0.001
Smoking status at diagnosis
Non-smoker 723 (76.9) 359 (72.1) 1082 (75.2)
Smoker 176 (18.7) 126 (25.3) 302 (21.0)
Unknown 41 (4.4) 13 (2.6) 54 (3.8) 0.006
Smoking status at latest follow up
Non-Smoker 799 (85.0) 420 (84.3) 1219 (84.8)
Smoker 126 (13.4) 73 (14.7) 199 (13.8)
Unknown 15 (1.6) 5 (1.0) 20 (1.4) 0.547
https://doi.org/10.1371/journal.pone.0211554.t005
IBD and joint manifestations
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Chronology of arthritis/arthralgia in CD and UC/IBDU patients
Finally, we studied whether arthritis/arthralgia appear as first or subsequent EIM in IBD
patients. We found that 50 years after IBD diagnosis almost every patient suffered from arthri-
tis/arthralgia (Fig 1). Arthritis/arthralgia seem to present rather as first EIM than as subsequent
Table 6. Disease characteristics (disease location, disease activity), disease complications and other EIMs in relation to joint EIM in UC/IBDU patients.
No Joint EIM Joint EIM All UC/IBDU pat. pvalue
Number of patients 940 (65.4) 498 (34.6) 1438 (100.0)
Initial disease location
Pancolitis 348 (37.0) 191 (38.4) 539 (37.5)
Left-sided colitis 309 (32.9) 153 (30.7) 462 (32.1)
Proctitis 190 (20.2) 93 (18.7) 283 (19.7)
Unclear/Unknown 93 (9.9) 61 (12.3) 154 (10.7) 0.440
Last disease location
Pancolitis 328 (34.9) 168 (33.7) 496 (34.5)
Left-sided colitis 335 (35.6) 187 (37.6) 522 (36.3)
Proctitis 171 (18.2) 84 (16.9) 255 (17.7)
Unclear/Unknown 106 (11.3) 59 (11.9) 165 (11.5) 0.833
MTWAI at enrollment
(median, IQR, range)
2, 1–5, 0–19 3, 1–6, 0–18 2, 1–5, 0–19 <0.001
MTWAI at latest follow-up
(median, IQR, range)
1, 0–3, 0–18 2, 1–4, 0–18 2, 0–4, 0–18 <0.001
IBD-related surgery 82 (8.7) 78 (15.7) 160 (11.1) <0.001
Anemia
During SIBDCS follow-up 252 (29.3) 165 (34.2) 417 (31.1) 0.067
At latest follow-up 82 (13.1) 52 (14.2) 134 (13.5) 0.622
Vit. B12 level at latest follow-up [pmo]/l)
(median, IQR, range)
299, 209–371, 54–1696 270, 202–363, 41–1476 279, 207–369, 41–1696 0.237
Ever received Vit. B12 Suppl. 139 (20.7) 116 (26.7) 255 (23.1) 0.021
Extraintestinal manifestations
Uveitis/Iritis 28 (3.0) 52 (10.4) 80 (5.6) <0.001
Pyoderma Gangrenosum 10 (1.1) 15 (3.0) 25 (1.7) 0.007
Erythema Nodosum 14 (1.5) 37 (7.4) 51 (3.5) <0.001
Aphtous/oral ulcers 22 (2.3) 57 (11.4) 79 (5.5) <0.001
Ankylosing spondilitis 14 (1.5) 30 (6.0) 44 (3.1) <0.001
PSC 40 (4.3) 21 (4.2) 61 (4.2) 0.973
any of the above 112 (11.9) 157 (31.5) 269 (18.7) <0.001
https://doi.org/10.1371/journal.pone.0211554.t006
Table 7. Treatment history and appearance of joint manifestations in UC/IBDU patients.
No Joint EIM Joint EIM All UC/IBDU pvalue
Number of patients 940 (65.4) 498 (34.6) 1438 (100.0)
Treatment history
5-ASA 885 (94.1) 478 (96.0) 1363 (94.8) 0.136
Antibiotics 86 (9.1) 72 (14.5) 158 (11.0) 0.002
Steroids 103 (74.8) 439 (88.2) 1142 (79.4) <0.001
Immunomodulators 529 (56.3) 353 (70.9) 882 (61.3) <0.001
Anti-TNF 286 (30.4) 215 (43.2) 501 (34.8) <0.001
Calcineurin inhibitors 79 (8.4) 60 (12.0) 139 (9.7) 0.026
https://doi.org/10.1371/journal.pone.0211554.t007
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EIM–this applies for all IBD patients together (83.3% reported arthritis/arthralgia as first EIM
vs. 16.7% who reported arthritis/arthralgia as subsequent EIM, p = 0.449). 80.4% of all IBD
patients reported arthritis/arthralgia occurrence after the diagnosis of IBD.
Ankylosing spondilitis/Sacroliitis in IBD patients
We next performed a further analysis of our patient collective of 3298 patients and analyzed
the associations of the clinical presentation of the patients and the presence or absence of
sacroiliitis/ankylosing spondylitis. We found that only 155 (8.3%) of the 1860 CD patients
were suffering from specifically sacroiliitis/ankylosing spondylitis compared to 907 (48.8%) of
our CD patients suffering from arthralgia/arthritis. CD patients with sacroiliitis/ankylosing
spondylitis were in general older at diagnosis than patients without sacroiliitis/ankylosing
spondylitis during disease course (29 vs 26 years), but featured a longer disease duration (15 vs
13 years). While they did not reveal more CD-related complications, such as fistulas, abscesses
or stenosis, or surgeries, they more frequently received vitamin B12 supplementation, mesala-
zin (5-ASA) and anti-TNF antibodies when compared to CD patients without sacroiliitis/
ankylosing spondylitis. Notably CD patients with sacroiliitis/ankylosing spondylitis suffered
significantly more often from other EIM, such as uveitis, iritis, erythema nodosum or
aphthous/oral ulcers (Table 9).
Only 63 (4.4%) of the 1438 UC/IBDU patients suffered from specifically sacroiliitis/anky-
losing spondylitis compared to 498 (34.6%) of our UC/IBDU patients suffering from arthral-
gia/arthritis. UC/IBDU patients with sacroiliitis/ankylosing spondylitis received more
frequently vitamin B12 supplementation and anti-TNF antibodies when compared to UC/
IBDU patients without sacroiliitis/ankylosing spondylitis. Similar to CD patients, also UC/
IBDU patients with sacroiliitis/ankylosing spondylitis suffered significantly more often from
other EIM, such as uveitis, iritis or aphthous/oral ulcers (Table 10).
Finally, we found that 50 years after IBD diagnosis about 20% of patients suffered from
sacroiliitis/ankylosing spondylitis (Fig 2). Similar to arthritis/arthralgia, also sacroiliitis/anky-
losing spondylitis is reported rather as first EIM than as subsequent EIM–this applies for all
Table 8. Multivariate logistic regression results for UC patients.
Outcome: Joint EIM OR (95% CI) pvalue
Gender
Male 1 (ref)
Female 1.792 (1.346–2.387) <0.001
Age at diagnosis [per year] 1.027 (1.016–1.039) <0.001
Disease duration [per year] 1.040 (1.024–1.057) <0.001
Smoking status at diagnosis
Non-smoker (ref) 1 (ref)
Smoker 1.705 (1.214–2.395) 0.002
IBD-relates surgery
None (ref) 1 (ref)
Yes 1.542 (1.040–2.285) 0.031
Anti-TNF treatment
Never (ref) 1 (ref)
Yes 1.644 (1.231–2.196) 0.001
Other EIM
No (ref) 1 (ref)
Yes 3.132 (2.239–4.381) <0.001
https://doi.org/10.1371/journal.pone.0211554.t008
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IBD patients together (76.1% reported sacroiliitis/ankylosing spondylitis as first EIM vs. 23.9%
who reported sacroiliitis/ankylosing spondylitis as subsequent EIM, p = 0.702). 39.1% reported
sacroiliitis/ankylosing spondylitis already before IBD diagnosis.
Discussion
In this study, we aimed to find epidemiologic and clinical risk factors for the occurrence of
arthritis/arthralgia in patients suffering from IBD. We found that females are more likely to
develop arthritis/arthralgia regardless whether they suffer from CD or UC. This observation is
in good accordance with previous data from the SIBDCS, where 50% of the female CD
patients, but only 34% of male CD patients suffered from any EIM [1, 18]. Male IBD patients
however, more commonly present with axial arthropathies than female patients [3, 19]. Our
study has now analyzed the presence of EIM in more detail and focused on arthritis/arthralgia
and, in a second step, on the subgroup of patients with sacroiliitis/ankylosing spondylitis.
We found that arthritis/arthralgia are more common in CD and UC/IBDU patients with a
higher disease activity. This might be plausible, since patients with more severe intestinal
inflammation are also likely to suffer more frequently from pain overall and therefore also
from joint pain. This finding has already been described for UC patients in a study from 1990,
Fig 1. Cumulative proportion of arthritis / arthralgia.
https://doi.org/10.1371/journal.pone.0211554.g001
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Table 9. Clinical associations of CD patients with ankylosing spondilitis / sacroliitis.
No Anky spond./Sacro Anky spond./Sacro All CD patients pvalue
Number of patients 1705 (91.7) 155 (8.3) 1860 (100.0)
Gender
Male 818 (48.0) 68 (43.9) 886 (47.6)
Female 887 (52.0) 87 (56.1) 974 (52.4) 0.327
Age at diagnosis [y] (median,IQR, range) 26, 20–36,1–81 29, 22–41, 11–71 26, 20–37, 1–81 0.010
Age at latest follow-up [y] (median, IQR, range) 44, 33–56, 16–94 49, 37–60, 22–84 44, 33–57, 16–94 0.003
Disease duration [y]
(median, IQR, range)
13, 7–22, 0–57 15, 9–22, 0–46 13, 7–22, 0–57 0.049
BMI at latest follow-up [kg/m2]
(median, IQR, range)
23, 20–26, 14–43 23, 22–25, 19–29 23, 20–26, 14–43 0.882
Initial disease location
L1 408 (23.9) 37 (23.9) 445 (23.9)
L2 329 (19.3) 37 (23.9) 366 (19.7)
L3 763 (44.8) 66 (42.3) 829 (44.6)
L4 only 13 (0.8) 1 (0.7) 14 (0.8)
Unclear/Unknown 192 (11.3) 14 (9.0) 206 (11.1) 0.661
Last disease location
L1 469 (27.5) 52 (33.6) 521 (28.0)
L2 522 (30.6) 34 (21.9) 556 (29.9)
L3 469 (27.5) 44 (28.4) 513 (27.6)
L4 only 41 (2.4) 6 (3.9) 47 (2.5)
Unclear/Unknown 204 (12.0) 19 (12.3) 223 (12.0) 0.153
CDAI at enrollment (median, IQR, range) 33, 11–74, 0–435 53, 26–91, 0–450 34, 12–76, 0–450 <0.001
CDAI at latest follow-up (median, IQR, range) 20, 6–48, 0–395 40, 20–83, 0–345 21, 6–51, 0–395 <0.001
Smoking status at diagnosis
Non-smoker 845 (49.6) 69 (44.5) 914 (49.1)
Smoker 781 (45.8) 84 (54.2) 865 (46.5)
Unknown 79 (4.6) 2 (1.3) 81 (4.4) 0.034
Smoking status at latest follow-up
Non-smoker 1158 (67.9) 105 (67.7) 1263 (67.9)
Smoker 534 (31.3) 50 (32.3) 584 (31.4)
Unknown 13 (0.8) 0 (0.0) 13 (0.7) 0.773
CD-related complications
Perianal Fistula 445 (26.1) 36 (23.2) 481 (25.9) 0.434
Other Fistula 283 (16.6) 20 (12.9) 303 (16.3) 0.233
Any Fistula 601 (35.2) 49 (31.6) 650 (34.9) 0.363
Abscess 419 (24.6) 42 (27.1) 461 (24.8) 0.486
Stenosis 733 (43.0) 71 (45.8) 804 (43.2) 0.498
CD-related surgery
Intestinal resection 701 (41.1) 0 (45.2) 771 (41.5) 0.327
Fistula/Abscess surgery 431 (25.3) 37 (23.9) 468 (25.2) 0.699
Any Surgery 874 (51.3) 81 (52.3) 955 (51.3) 0.812
Anemia
During SIBDCS follow-up 500 (29.9) 57 (37.3) 557 (30.5) 0.057
At latest follow-up 165 (12.3) 18 (14.4) 183 (12.5) 0.492
Vit. B12 level at latest follow-up [pmo]/l)
(median, IQR, range)
243, 178–324, 28–2435 242, 191–325, 74–1258 242, 178–325, 28–2435 0.802
Ever received Vit. B12 Suppl. 709 (50.6) 84 (61.8) 793 (51.6) 0.013
(Continued)
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where 70% of patients with extracolonic manifestations suffered from highly active UC [20].
We also found evidence that the disease duration is associated with the presence of arthritis/
arthralgia as well. After 5 years about 25% of CD patients suffer from arthritis/arthralgia and
after 15 years, already about 50% of CD patients suffer from such manifestations. A longer dis-
ease duration and a higher disease activity are plausible markers for a severe disease course
that is also associated with intestinal surgery due to IBD. Cleynen et al. have nicely shown that
the time between diagnosis of IBD and occurrence of complications or surgery is dependent
on disease location, particularly colonic inflammation, in CD patients [21], whereas for UC
patients, disease progression is mainly dependent on the extent of the inflammation [21]. We
found that a longer disease duration as well as higher disease activity are associated with the
presence of arthritis/arthralgia in IBD patients. A recent study further found that in pediatric
patients exhibiting a respectively young age at diagnosis what also hints towards a more severe
disease course, is associated with onset of EIM later on [22].
CD and UC/IBDU patients with arthritis/arthralgia were significantly more often treated
with anti-TNF when compared to patients without arthritis/arthralgia. This might on the one
hand reflect that patients with arthritis/arthralgia are suffering from a more severe disease and
therefore need more frequently anti-TNF treatment. On the other hand, anti-TNF antibodies
are commonly used for treating arthritis and arthritis/arthralgia in IBD patients. Those obser-
vations have also been confirmed in a pediatric cohort of IBD patients [23]. Of interest, pediat-
ric CD patients seem to suffer clearly more frequently from EIM and in particular joint EIM
than elderly-onset IBD patients [24].
Limitations of our analysis are certainly on the one hand that we are lacking the info which
joint EIM occurred before diagnosis of IBD and on the other hand, that joint disease associated
with IBD was not confirmed by a rheumatologist. This suggests that an accurate diagnosis of
the underlying diagnosis of arthritis/arthralgia might not be available in any patient. However,
to improve the quality of our data, we also analyzed the clinical associations of patients
Table 9. (Continued)
No Anky spond./Sacro Anky spond./Sacro All CD patients pvalue
Treatment history
5-ASA 965 (56.6) 104 (67.1) 1069 (57.5) 0.011
Antibiotics 311 (18.2) 29 (18.7) 340 (18.3) 0.885
Steroids 1468 (86.1) 134 (86.5) 1602 (86.1) 0.903
Immunomodulators 1386 (81.3) 128 (82.6) 1514 (81.4) 0.963
Anti-TNF 1059 (62.1) 121 (78.1) 1180 (63.4) <0.001
Calcineurin inhibitors 31 (1.8) 5 (3.2) 36 (1.9) 0.218
Extraintestinal manifestations
Arthritis/Arthalgia 770 (45.2) 137 (88.4) 907 (48.8) <0.001
Uveitis/Iritis 167 (9.8) 40 (25.8) 29 (1.6) <0.001
Pyoderma Gangrenosum 26 (1.5) 3 (1.9) 143 (7.7) 0.729
Erythema Nodosum 123 (7.2) 20 (12.9) 242 (13.0) 0.011
Aphtous/oral ulcers 203 (11.9) 39 (25.2) 128 (6.9) <0.001
PSC 10 (0.6) 2 (1.3) 12 (0.6) 0.264
any of the above 895 (52.5) 140 (90.3) 1035 (55.6) <0.001
Family history of IBD
None 1297 (76.1) 116 (74.8) 1413 (76.0)
Yes 222 (13.0) 28 (18.1) 250 (13.4)
Unknown 186 (10.9) 11 (7.1) 197 (10.6) 0.097
https://doi.org/10.1371/journal.pone.0211554.t009
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Table 10. Clinical associations of UC/IBDU patients with ankylosing spondilitis / sacroliitis.
No Anky spond./Sacro Anky spond./Sacro All UC/IBDU pat. pvalue
Number of patients 1375 (95.6) 63 (4.4) 1438 (100.0)
Gender
Male 741 (53.9) 32 (50.8) 773 (53.8)
Female 634 (46.1) 31 (49.2) 665 (46.2) 0.630
Age at diagnosis [y] (median,IQR, range) 31, 32–40, 3–83 31, 23–42, 12–66 321, 23–41, 3–83 0.644
Age at latest follow-up [y] (median, IQR, range) 46, 36–57, 17–89 47, 39–59, 22–79 46, 36–57, 17–89 0.256
Disease duration [y]
(median, IQR, range)
12, 7–19, 0–59 13, 9–18, 2–49 12, 7–19, 0–59 0.071
BMI at latest follow-up [kg/m2]
(median, IQR, range)
24, 22–27, 18–38 22, 19–27, 17–30 24, 22–27, 17–38 0.391
Initial disease location
Pancolitis 517 (37.6) 22 (34.9) 539 (37.5)
Left-sided colitis 435 (31.6) 27 (42.9) 462 (32.1)
Proctitis 272 (19.8) 11 (17.5) 283 (19.7)
Unclear/Unknown 151 (11.0) 3 (4.8) 154 (10.7) 0.205
Last disease location
Pancolitis 476 (34.6) 20 (31.8) 496 (34.5)
Left-sided colitis 496 (36.1) 26 (41.3) 522 (36.3)
Proctitis 243 (17.7) 12 (19.1) 255 (17.7)
Unclear/Unknown 160 (11.6) 5 (7.9) 165 (11.5) 0.746
MTWAI at enrollment (median, IQR, range) 2, 1–5, 0–19 4, 1–7, 0–15 2, 1–5, 0–19 0.010
MTWAI at latest follow-up (median, IQR, range) 2, 0–3, 0–18 3, 1–4, 0–18 2, 0–4, 0–18 0.059
Smoking status at diagnosis
Non-smoker 1034 (75.2) 48 (76.2) 1082 (75.2)
Smoker 288 (21.0) 14 (22.2) 302 (21.0)
Unknown 53 (3.8) 1 (1.6) 54 (3.8) 0.790
Smoking status at latest follow-up
Non-smoker 1168 (85.0) 51 (81.0) 1219 (84.4)
Smoker 187 (13.6) 12 (19.0) 199 (13.8)
Unknown 20 (1.4) 0 (0.0) 20 (1.4) 0.422
IBD-related surgery 149 (10.8) 11 (17.5) 160 (11.1) 0.102
Anemia
During SIBDCS follow-up 401 (31.3) 16 (26.7) 417 (31.1) 0.451
At latest follow-up 128 (13.5) 6 (13.6) 134 (13.5) 1.000
Vit. B12 level at latest follow-up [pmo]/l)
(median, IQR, range)
285, 208–371, 41–1696 242, 201–324, 110–1476 279, 207–369, 41–1696 0.261
Ever received Vit. B12 Suppl. 235 (22.4) 20 (35.1) 255 (23.1) 0.027
Treatment history
5-ASA 1302 (94.7) 61 (96.8) 1363 (94.8) 0.456
Antibiotics 150 (10.9) 8 (12.7) 158 (11.0) 0.657
Steroids 1088 (79.1) 54 (85.7) 1142 (79.4) 0.206
Immunomodulators 836 (60.8) 46 (73.0) 882 (61.3) 0.052
Anti-TNF 468 (34.0) 33 (52.4) 501 (34.8) 0.003
Calcineurin inhibitors 131 (9.5) 8 (12.7) 139 (9.7) 0.405
Extraintestinal manifestations
Arthritis/Arthalgia 453 (32.96) 45 (71.4) 498 (38.5) <0.001
Uveitis/Iritis 64 (4.7) 16 (25.4) 25 (1.7) <0.001
Pyoderma Gangrenosum 21 (1.5) 4 (6.3) 51 (3.5) 0.021
(Continued)
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suffering from sacroiliitis/ankylosing spondylitis as a clear and accurate diagnosis. Interest-
ingly, though for this patient group, the number of affected patients was clearly less, we found
comparable disease characteristics.
With respect to our data, however, a recent publication by Ossum et al. it noteworthy.
Here, using the inception cohort from the IBSEN study, the authors followed IBD patients
Table 10. (Continued)
No Anky spond./Sacro Anky spond./Sacro All UC/IBDU pat. pvalue
Erythema Nodosum 47 (3.4) 6 (6.4) 79 (5.5) 0.279
Aphtous/oral ulcers 70 (5.1) 9 (14.3) 44 (3.1) 0.002
PSC 58 (4.2) 3 (4.8) 61 (4.2) 0.747
any of the above 550 (40.0) 52 (82.5) 602 (41.9) <0.001
Family history of IBD
None 1087 (79.1) 51 (81.0) 1138 (79.1)
Yes 141 (10.2) 0 (14.3) 150 (10.4)
Unknown 147 (10.7) 3 (4.7) 150 (10.4) 0.210
https://doi.org/10.1371/journal.pone.0211554.t010
Fig 2. Cumulative proportion of ankylosing spondylitis / sacroliitis.
https://doi.org/10.1371/journal.pone.0211554.g002
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prospectively for 20 years with respect to the prevalence of IBD-related peripheral arthritis and
peripheral spondyloarthritis. The authors found that prevalence of developing disease- (IBD-)
related peripheral arthritis or peripheral spondyloarthritis during disease course was 17.2% or
27.9%, respectively. Those data are somehow in the range that we observe in our study using
the patient collective of the SIBDCS. In line with our data, also in the IBSEN study, more
women than men suffered from IBD-related peripheral arthritis and peripheral spondyloar-
thritis [25]. Those data are also in line with data from India. In this study, a trained rheumatol-
ogist confirmed the diagnosis and prevalence for joint EIM was found to be 23% for peripheral
arthritis and 18% for ankylosing spondylitis during disease course [26]. In contrast, a previous
study from Europe reported a clearly lower prevalence for unspecified arthritis as EIM in
European IBD patients [27].
Of note, we detected no increased risk to develop joint EIM in smoking CD patients com-
pared to non-smoking CD patients and observed that smoking UC patients are actually pro-
tected from the onset of joint EIM when compared to non-smoking UC patients. This is in
contrast to data from Severs et al. who found by analyzing data from three large cohorts that
joint manifestations might be more prevalent in IBD patients that smoke than in those who
not smoke. Interestingly, they found this association for both, CD and UC patients [28]. At
least for UC patients, this finding is somehow surprising, since smoking is generally consid-
ered to protect from UC and to be associated with a less severe disease course in UC patients
[29].
In conclusion, we found a more severe disease course to be associated with arthritis/arthral-
gia, but also with sacroiliitis/ankylosing spondylitis in IBD patients. In particular, anti-TNF
treatment, onset of further EIM and IBD-related surgery which are all indicative of a severe
course of disease, are risk factors for the presence of arthritis/arthralgia, but also with sacroilii-
tis/ankylosing spondylitis in IBD patients.
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